|
|
 |
| |
|
|
| |
|
|
| |
|
| Synonyms: |
Rebeprazole sodium, dexrabeprazole, Eraloc, Rabeprazole (INN), Eraloc (TN), AC1L1JGC, Rabeprazole [BAN:INN],
|
| Chemical Name: |
(RS)-2-([4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole |
| Molecular Formula: |
|
| Molecular Weight : |
359.444 |
| CAS No. : |
117976-89-3 |
| Chemical Structure: |
|
| Specification: |
USP/EP |
Pharmacodynamic
Properties: |
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It was developed by Eisai Co. and is marketed by Janssen-Cilag as rabeprazole sodium under the brand names AcipHex ( referring to pH) in the US, Pariet in Europe, Brazil, Canada, Japan, Russia and Australia, and Razo and Parit in India.
Short-term treatment in healing and symptomatic relief of duodenal ulcers and erosive or ulcerative gastroesophageal reflux disease (GERD); maintaining healing and reducing relapse rates of heartburn symptoms in patients with GERD; treatment of daytime and nighttime heartburn and other symptoms associated with GERD; long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome and in combination with amoxicillin and clarithromycin to eradicate Helicobacter pylori.
• Gastric ulcer (GU)
• Peptic ulcer disease (PUD)
• Maintenance of healing of erosive or ulcerative GERD
• Healing of erosive and ulcerative GERD
• Healing of duodenal ulcers.
• Treatment of symptomatic GERD
• Treatment of pathological hypersecretory conditions (Zollinger-Ellison syndrome)
• Helicobacter pylori eradication to reduce risk of duodenal ulcer recurrence
|
| Storage: |
Keep container tightly closed in a cool, well-ventilated area. |
| MSDS: |
Provide as per request after the order or contract is signed. |
|
|
| |
[Disclaimer]
(1) All rights reserved. Reproduction in whole or part expressly forbidden without written permission.
(2) We make effort to ensure the information presented here is accurate, but does not purport to be all inclusive and shall be used only as a reference.
(3) We make no warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. |
|
 |
|
|
